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Abstract
Purpose: Patients with close or positive margins after surgery for pancreatic carcinoma are at a
high risk for recurrence. Stereotactic body radiation therapy (SBRT) allows for safe dose escalation
with great conformity and short duration of treatment. Herein, we report the initial results of a
prospective observational study that evaluated the efficacy and safety of this treatment option.
Methods and Materials: Patients eligible for the study had pathologically proven T1-4N0-1M0
pancreatic adenocarcinoma with a positive margin (1 mm) or a close margin defined as <2.5 mm.
Patients were treated with either neoadjuvant or adjuvant chemotherapy, if eligible for systemic
therapy. All patients received 36 Gy in 3 fractions to the close or positive margin site.
Results: From February 2013 to January 2018, 50 patients were enrolled with 49 patients treated
on protocol and included in the analysis. The median age was 71 years. The median clinical target
volume was 11.3 cc and median planning target volume 22.0 cc. The median overall survival was
23.7 months (95% confidence interval, 13.6-33.8). Local progression-free survival at 1 and 2 years
was 85% and 77%, respectively. Regional progression-free survival at 1 and 2 years was 73% and
73%, respectively. Distant metastases-free survival was 57% and 49% at 1 and 2 years,
respectively. Grade 3þ radiation toxicity was only 4.1% and occurred in 2 patients.
Conclusions: Adjuvant pancreatic SBRT was shown to be a safe and feasible treatment option for
patients with high-risk pancreatic adenocarcinoma and close or positive margins. This is the first
prospective study of SBRT in high-risk postoperative pancreatic cancer. Our results yielded
significant local and regional control with low rates of acute toxicity. This technique does not
interrupt the administration of systemically dosed multiagent chemotherapy and can be safely
interdigitated between cycles because SBRT is only 1 week of treatment.
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Introduction
Surgery remains the standard of care for patients with
resectable pancreatic adenocarcinoma.1,2 Adjuvant
therapy consists of chemotherapy, with the addition of
adjuvant radiation reserved for select cases.1e3 Even for
patients who receive surgical resection and adjuvant
therapy, outcomes remain poor with a median survival of
28 months and a 5-year overall survival (OS) of
approximately 20% to 25%.1e3
Prognostic factors associated with outcomes for
surgically staged patients include tumor grade, tumor size,
lymph node status, surgical margin status, and perineural
or blood vessel invasion.4 Numerous reports have
demonstrated that patients who receive an R1 resection
with margins 1 mm are at an increased risk of
recurrence with worse survival rates.3e6 The impact that
margin status has on survival is evident, even with
dual-agent chemotherapy, and necessitates additional
therapy.1
Multiagent adjuvant chemotherapy has been shown to
improve survival, but the addition of radiation therapy is
controversial, and prior studies have shown conflicting
results.7,8 However, patients with less than an R0
resection margin may likely benefit from further local
therapy. If adjuvant chemoradiation is administered,
treatment usually involves conventional fractionation that
consists of approximately 5 to 6 weeks of treatment with
concurrent chemotherapy.8,9 However, this regimen may
result in delays in systemic dosing of chemotherapy,
which theoretically could increase the risk of distant
metastasis.
Adjuvant stereotactic body radiation therapy (SBRT)
presents a great opportunity to adequately treat patients
with close or positive margins. The highly conformal
nature of SBRT allows for a higher dose to be
administered within 3 to 5 treatments while minimizing
doses to surrounding critical structures.10,11 In addition,
the abbreviated treatment course prevents long delays for
the initiation of systemically dosed chemotherapy, which
may assist in reducing the risk of distant metastasis.
Pancreatic SBRT has been shown to be efficacious in
the borderline-resectable and locally advanced
setting.10,11 We previously conducted a retrospective
review of adjuvant pancreatic SBRT for close or positive
margins.3 We now report the initial results of a
prospective observational study that evaluated the use of
SBRT in the adjuvant setting for this high-risk subset of
patients.
Methods and Materials
Enrollment and eligibility
All patients had pathologically proven T1-4N0-1M0
pancreatic adenocarcinoma with a positive margin (direct
positive and 1 mm) or a close margin defined as
<2.5 mm. Patients were age 18 years, had an estimated
life expectancy of >12 weeks, and a Karnofsky
performance status score of 70 (Eastern Cooperative
Oncology Group score 0-1). Other criteria included
adequate renal function, adequate hepatic function, being
able to swallow enteral medications with no feeding tube,
no uncontrolled intercurrent illness, and not pregnant or
nursing. All patients were treated with surgical resection
and had either neoadjuvant chemotherapy or adjuvant
chemotherapy if eligible to receive systemic therapy. All
patients were treated at UPMC Hillman Cancer Center,
Department of Radiation Oncology with approval from an
institutional review board to conduct the study. This trial
was prospectively registered with ClinicalTrials.gov
identifier NCT01357525.
Pancreatic stereotactic body radiation therapy
planning
Contrast-enhanced computed tomography (CT)-based
simulations were obtained before any adjuvant treatment
(2-4 weeks postoperative, depending on healing). The
treatment volume was contoured on axial CT images
obtained at 1.25 mm slice thickness. The volumes were
then reconstructed into a 3-dimensional image set for
SBRT planning. Subjects were simulated in the
treatment position (ie, supine with arms raised) on the CT
scanner table with the appropriate immobilization and a
vacuum lock bag. Optiray contrast (125 mL Optiray 350;
350 mg/mL organically bound iodine; Ioversol;
Mallinckrodt Inc, St. Louis, MO) was administered
intravenously at a flow rate of 2.5 mL/s. A helical CT
scan of the abdomen was acquired with intravenous
contrast starting 30 seconds before CT acquisition.
Four-dimensional CT data acquisition for the same
axial extent was also obtained. Based on the axial CT
images, fiducial marker placement (ie, 3 fiducials placed
at the discretion of the surgeon), review of the pathology
report, and a detailed discussion with the operating
surgeon, the contours were drawn of the clinical target
volume (CTV), which was defined as the area at risk for
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microscopic disease based on the pathology report and per
the surgeons as marked by clips and fiducials. The CTV
only included the area of the close or positive margin and
was not altered for nodal status. Preoperative tumor
volume was not used to determine the CTV. The planning
target volume (PTV) was the CTV þ 2 mm, unless
motion was detected on the 4-dimensional motion study.
In addition, no margin was added to the CTV if it was
adjacent to the bowel. If there was motion, the margin
given was the amount of motion in the superioreinferior,
lateral, and anterioreposterior directions. The surround-
ing normal and critical structures were also contoured by
the treating radiation oncologist, including the kidneys,
liver, small bowel, spinal cord, and stomach if necessary.
Patients were treated with a dose of 36 Gy in 3 fractions,
with 12 Gy per fraction prescribed to the PTV (Fig 1) every
other day. This dose regimen was chosen based on our
prior institutional experience with multifractionated
pancreatic SBRT.12 Patients were treated either using
volumetric modulated arc therapy or static field intensity
modulated radiation therapy with image guidance, using
daily cone beam CT with localization of fiducials. No more
than 2% of the PTV could receive <93% of the prescribed
dose. The maximum dose (in 3 fractions) was limited to
sensitive critical structures, including the liver (15 Gy),
kidney (15 Gy), spinal cord (18 Gy), stomach (30 Gy), and
small bowel (30 Gy). Patients were followed up 10 to
12 weeks after SBRT, then every 3 months, and thereafter
for up to 24 months, with CT scans obtained at each
follow-up visit.
Primary endpoints
Our primary, prospectively defined endpoint was local
progression-free survival (LPFS). Secondary endpoints
include OS, regional progression-free survival (RPFS),
distant metastases-free survival (DMFS), toxicity, and
quality of life. OS was measured from enrollment, and
LPFS, RPFS, and DMFS were all measured from
completion of the SBRT. Local progression was defined
as disease recurrence detected on follow-up imaging
(CT or 18-fluoro-deoxyglucose positron emission
tomography/CT) that was located with the SBRT target
volume. Regional failure was defined as disease
progression to the regional nodes, defined as N1, N2, or
N3 by the Japan Pancreas Society classification13,14
(or new tumor growth within the pancreas outside of
the radiation field). Toxicity was graded and recorded
prospectively with the Common Terminology Criteria for
Adverse Events, version 4.0 at each follow-up visit.
Patient-reported quality of life was assessed with the
Functional Assessment of Cancer Therapy-General
questionnaire before and within 3 months of completion
of the SBRT.
Statistical analysis
Continuous variables were summarized with median
and interquartile range. Categorical variables were
summarized with frequency and percentage. Median
follow-up was calculated with reverse Kaplan-Meier.15
The survival endpoints (OS and time to progression)
were analyzed with the Kaplan-Meier method. The
association of these survival endpoints with risk factors
was studied with univariate Cox proportional hazards
models. To build the multivariable Cox models for the
survival endpoints, a stepwise variable selection was
performed. All variables from the univariate models that
had P < .1 were included as potential predictors.
Variables were removed from the multivariable model if
Figure 1 Example of a stereotactic body radiation therapy treatment plan. The orange volume represents the planning target volume
(PTV). Of note, the dose to the small bowel takes priority of the PTV coverage. Also, the PTV is the same as the clinical target volume
for areas that touch the bowel.
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P > .05. All P-values reported are 2-sided. For the quality
of life analysis, the total Functional Assessment of Cancer
Therapy-General score was compared using the Wilcoxon
signed rank test between pre- and post-SBRT.
Results
Patient characteristics and treatment delivery
A detailed list of patient characteristics can be found in
Table 1. From February 2013 to January 2018, 50 patients
were enrolled and 49 patients were treated. One patient
was unable to receive SBRT owing to treatment not
covered by insurance; therefore, the patient was excluded
from the analysis. The median age was 69.9 years (range,
62.2-75.6 years). Male patients comprised 53.1% of our
cohort. The tumors were located in the pancreatic head or
uncinate process in 81.6% and body in 18.4% of patients.
At the time of diagnosis, patients had either resectable
(55.1%), borderline resectable (42.9%), or locally
advanced (2.0%) disease. Patients received neoadjuvant
(65.3%) and adjuvant (81.6%) chemotherapy. After
resection, 38 patients (77.6%) had a positive margin
(1 mm) and 11 patients (22.4%) had a close margin
(median: 2 mm; range, 1.5-2.0). The median CTV and
PTV were 11.3 cc and 22.0 cc, respectively. One patient
received 30 Gy in 10 fraction because dose constraints
could not be met with 36 Gy. The interval from surgery
was 63 days (interquartile range, 48-84 days). SMAD4
was obtained for all patients, except 6, and lost in 53.1%
of patients. The median follow-up time was 31.2 months
(95% confidence interval [CI], 13.7-48.7 months).
Overall survival
The median survival for the entire cohort was
20.03 months (95% CI, 12.8-27.3 months). The 1- and
2-year OS rates were 68% and 50%, respectively (Fig 2).
No variables were found to be associated with OS on the
Table 1 Patient characteristics
Characteristics No (%)
(n Z 49 lesions)
Age (median years, range) 69.9 (62.2-75.6)
Sex
Female 23 (46.9)
Male 26 (53.1)
Stage
T3N0 13 (26.5)
T3N1 36 (73.5)
Grade
Well 0 (0)
Moderate 33 (69.4)
Poor 14 (28.6)
Undifferentiated 1 (2.0)
Resectability at time of diagnosis
Resectable 27 (55.1)
Borderline resectable 21 (42.9)
Locally advanced 1 (2.0)
SMAD4 status
Preserved 17 (34.7)
Lost 26 (53.1)
Unknown 6 (12.2)
Cancer antigen 19-9 value
(median value, IQR)
Diagnosis 120.6 (36.0-379.5)
Postoperative 20.3 (8.8-71.6)
Post-SBRT 26.5 (11.3-96.1)
Post-SBRT cancer antigen 19-9
normalization
Yes 10 (22.0)
No 11 (20.0)
Unknown 29 (58)
Margins
Close 11 (22.4)
Positive 38 (77.6)
Location
Head/uncinate 40 (81.6)
Body 9 (18.4)
Treatment platform
True beam 29 (59.2)
Trilogy 20 (40.8)
Chemotherapy
Neoadjuvant 32 (65.3)
Gemcitabine 2 (4.1)
Gemcitabine þ Pb-paclitaxel 25 (51)
Folfirinox 5 (10.2)
Median duration of neoadjuvant, days
(IQR)
44 (37.5-67)
Adjuvant 40 (81.6)
Gemcitabine 11 (22.4)
Gemcitabine þ Pb-paclitaxel 11 (22.4)
Gemcitabine þ capecitabine 8 (16.3)
5-fluorouracil based 6 (12.2)
Other 4 (8.2)
Median duration of adjuvant, days
(IQR)
126 (91-150)
(continued on next column)
Table 1 (continued )
Characteristics No (%)
(n Z 49 lesions)
Median duration from SBRT to start of
adjuvant, days (IQR)
7 (7 to 18)
Clinical target volume, cc (median, IQR) 11.3 (7.0-15.7)
Planning target volume, cc (median, IQR) 22.0 (15.1-27.7)
Dose (median, range) 36 (30-36)
Interval from surgery (median days, IQR) 63 (48-84)
Abbreviations: IQR Z interquartile range; SBRT Z stereotactic
body radiation therapy.
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univariate cox regression analysis (Table 2). No
significant difference in OS was observed between close
(median OS: 32.6 months) and positive margins (median
OS: 17.8 months), but OS trended toward significance on
the log rank (P Z .066; c2 Z 3.374).
Local progression-free survival
Local failure was observed in 6 patients (12.5%), and
the median time to local progression was not reached. The
1- and 2-year LPFS were 85% and 77%, respectively
(Fig 2). On univariate analysis, no predictors were
significantly associated with LPFS, but CTV (continuous;
P Z .051; hazard ratio [HR]: 1.050; 95% CI, 1.000-
1.103) and neoadjuvant chemotherapy (P Z .071; HR:
0.129; 95% CI, 0.014-1.196) demonstrated a trend toward
significance (Table 2). The multivariate analysis using
predictors that trended toward significance on univariate
analysis identified increased CTV (PZ .038; HR: 1.095;
95% CI, 1.005-1.193) associated with inferior LPFS.
Regional progression-free and distant
metastasis-free survival
The median time-to-regional progression was not
reached; however, the 1- and 2-year RPFS rates were 73%
and 73%, respectively (Fig 2). On univariate analysis, un-
differentiated versus moderately differentiated pancreatic
cancer (P Z .009; HR: 28.171; 95% CI, 2.343-338.755)
was associated with inferior RPFS (Table 3). A multivariate
model was unable to be generated. The median DMFS was
20.0 months (95% CI, 0.0-40.0) with 1- and 2-year DMFS
rates of 57% and 49%, respectively (Fig 2). The median
time-to-distant metastasis was 20.0 months (95% CI,
0.0-40.0 months). Post-SBRT cancer antigen 19-9
(P Z .002; HR: 1.001; 95% CI, 1.000-1.001), cancer
antigen 19-9 normalization (PZ .025; HR: 0.084; 95% CI,
0.010-0.731), and undifferentiated versus moderately
differentiated (P Z .038; HR: 9.965; 95% CI,
1.133-87.638) were found to be significantly associated
with distant metastases (Table 3). No variables were found
to be predicative of DMFS on multivariate analysis.
Radiation toxicity and quality of life
Two patients (4.1%) experienced acute grade
3 þ radiation toxicity. Toxicity included grade 3
abdominal pain (n Z 1) and hyperglycemia (n Z 1),
which both required hospitalization within 1 week after
treatment. No patients experienced late grade 3þ toxicity.
After treatment, there was no significant difference in
patient-reported quality of life (Z Z 0.700; P Z .484).
Discussion
Surgery remains the standard of care for resectable
pancreatic adenocarcinoma, but adjuvant radiation has
Figure 2 Kaplan-Meier curves of overall survival, local progression-free survival, regional progression-free survival, and distant
progression-free survival
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remained controversial.16e18 However, studies that
addressed the role of adjuvant radiation used
outdated techniques and included patients with both R0
and R1 resection. Margin status remains a potent
predictor for recurrence and survival.3e6 We recognize
that there is no standard definition for close margins in
the pancreatic adenocarcinoma literature. Close margin
has been reported as >1 to 2.5 mm.3,19 Our definition of
close margins was based on our previous retrospective
report.11 Adjuvant chemotherapy has been shown
to reduce recurrence, and improve survival for
resectable pancreatic adenocarcinoma; however, even
after aggressive systemic therapy, a positive margin is
associated with poor outcomes.1,2 SBRT represents a
promising modality to provide additional local control
and improve outcomes.
Table 2 Univariate and multivariate analysis for OS and FFLP
Factor OS
HR (95% CI)
P-value FFLP
HR (95% CI)
P-value
Univariate
Age 1.001 (0.978-1.043) .5504 0.947 (0.883-1.015) .124
Pretreatment CA 19-9 at time of diagnosis (continuous) 1.000 (1.000-1.000) .742 1.000 (1.000-1.000 .108
Postoperative CA 19-9 (continuous) 1.000 (0.999-1.002) .806 1.003 (0.997-1.009) .345
Post-SBRT CA19-9 (continuous) 1.000 (1.000-1.000) .265 1.00 (1.00-1.001) .360
CA 19-9 normalization 0.381 (0.062-2.332) .297 0.009 (0.000-1356.451) .437
Tumor stage: T3N1 vs T3N0 1.997 (0.678-5.885) .209 3.009 (0.348-26.036) .317
Grade: Poor vs moderate 1.918 (0.825-4.460) .130 1.696 (0.267-10.755) .575
Neoadjuvant chemotherapy 0.618 (0.367-1.815) .618 0.129 (0.014-1.196) .071
Adjuvant chemotherapy 0.938 (0.345-2.547) .899 0.552 (0.062-4.954) .596
Positive vs close margins 2.685 (0.901-8.000) .076 0.401 (0.067-2.403) .317
Lymphovascular invasion: Yes vs no 1.046 (0.354-3.086) .935 0.801 (0.089-7.244) .843
Clinical target volume (continuous) 0.993 (0.958-1.029) .689 1.050 (1.000-1.103) .051
Planning target volume (continuous) 0.968 (0.921-1.017) .192 1.032 (0.938-1.135) .520
SMAD4 intact: Yes vs no 0.982 (0.421-2.292) .966 1.334 (0.243-7.326) .740
Multivariate
Clinical target volume - - 1.095 (1.005-1.193) .038
Abbreviations: CA Z cancer antigen; CI Z confidence interval; FFLP Z freedom from local progression; HR Z hazard ratio; OS Z overall
survival; SBRT Z stereotactic body radiation therapy.
Table 3 Univariate analysis for FFRP and FFDM
Factor FFRP
HR (95% CI)
P-value FFDM
HR (95% CI)
P-value
Univariate*
Age 1.024 (0.964-1.087) .443 0.983 (0.944-1.025) .426
Pretreatment CA 19-9 (continuous) 1.000 (1.000-1.000) .175 1.000 (1.000-1.000) .284
Postoperative CA 19-9 (continuous) 1.001 (0.999-1.003) .381 1.001 (1.000-1.003) .098
Post-SBRT CA 19-9 (continuous) 1.000 (1.000-1.000) .758 1.001 (1.000-1.001) .002
CA 19-9 Normalization 0.209 (0.021-2.063) .180 0.084 (0.010-0.731) .025
Borderline resectable vs resectable 1.638 (0.471-5.696) .437 1.832 (0.755-4.445) .181
Tumor stage: T3N1 vs T3N0 0.860 (0.249-2.973) .811 2.872 (0.822-10.029) .098
Grade: Poor vs moderate 1.992 (0.525-7.558) .311 2.451 (0.930-6.459) .070
Grade: Undifferentiated vs moderate 28.171 (2.343-338.755) .009 9.965 (1.133-87.638) .038
Neoadjuvant chemotherapy 1.439 (0.370-5.598) .600 1.029 (0.403-2.628) .952
Adjuvant chemotherapy 0.779 (0.168-3.622) .751 1.143 (0.325-4.013) .835
Positive vs close margins 1.079 (0.228-5.017) .924 1.482 (0.430-5.103) .533
Treatment platform: trilogy vs true beam 0.537 (0.142-2.028) .359 1.701 (0.700-4.130) .241
Lymphovascular invasion: Yes vs no 1.714 (0.217-13.546) .610 3.838 (0.511-28.796) .191
Clinical target volume 1.029 (0.991-1.068) .134 0.987 (0.936-1.041) .629
Planning target volume 1.021 (0.958-1.088) .522 0.955 (0.905-1.007) .091
SMAD4 intact: Yes vs no 0.896 (0.238-3.378) .871 0.824 (0.324-2.096) .684
Abbreviations: CA Z cancer antigen; CI Z confidence interval; FFDM Z freedom from distant metastases; FFRP Z freedom from regional
progression; HR Z hazard ratio; OS Z overall survival; SBRT Z stereotactic body radiation therapy.
* No multivariate model was found for FFRP or FFDM.
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Delpero et al conducted a prospective multicenter
study to determine impact of resection margin status after
pancreaticoduodenectomy.20 The prospective study
accrued 150 patients between 2008 and 2010. As
expected, patients with a least one R1 margin status had a
lower median survival rate than those with an R0 margin
status (17.7 vs 32.9 months) and a lower median
progression-free survival rate (10.5 vs 19.5 months).
The Massachusetts General Hospital conducted a
retrospective review of 1705 patients with pancreatic
ductal adenocarcinoma to determine whether margin
status had any prognostic significance.19 They included
R0-close, which was a margin status of 1 mm. The
results showed a survival difference between R0 versus
R1 (24 vs 14 months). Although there was no difference
in survival time between R0-close and R1, an R0-wide
margin of >1 mm was associated with a longer survival
time compared with R1 or R0-close (34 vs 14 vs
16 months).
Washington University also conducted a retrospective
review of 285 patients between 1997 and 2008 who were
postpancreaticoduodenectomy to correlate margin status
with survival and recurrence.21 The results also showed that
R1 resections were associated with a lower median survival
time compared with R0 resections (16.4 vs 21.7 months)
and a lower local recurrence-free survival rate. A subset
analysis showed that a posterior positive margin was the
only site to increase the risk for lower local recurrence-free
survival. However, how many patients received adjuvant
chemotherapy is unclear, and whether the optimized
regimens used in the modern era is also unsure.
ESPAC-4 was a recent randomized controlled trial that
compared adjuvant gemcitabine with or without
capecitabine for resected pancreatic adenocarcinoma.1 The
study allowed both R0 and R1 resections to be included.
Although the addition of capecitabine improved themedian
survival time, there was a difference in outcomes for
patients who received an R0 or R1 resection. In the
multiagent chemotherapy group, patients with an R1
resection had a statistically significant lowermedian overall
survival time compared with those who received an R0
resection (23.7 vs 39.5 months). Among all patients who
received dual chemotherapy, 46% experienced a local
relapse. Our results demonstrated a similar survival time
but significantly improved local control with only 12% of
patients experiencing local recurrence.
Rwigema et al previously reported on a retrospective
review of 24 patients who were treated with adjuvant
SBRT for resected pancreatic cancer with close or
positive margins. In a median follow-up period of
12.5 months, the 2-year OS and freedom-from-local-
progression rates were 57.2% and 44%, respectively. No
patients experienced grade 3þ toxicity.3 Our study
demonstrated significantly better local control rates with
77% LPFS at 2 years. Suss et al reported on 1392 patients
who were treated with either chemoradiation or
chemotherapy. Radiation improved the median survival
time from 15.2 to 17.5 months. The addition of adjuvant
radiation did not significantly change the median survival
time among patients with node-negative disease (22.5 vs
23.6 months).22
To date, this is the first prospective report to show the
feasibility of adjuvant SBRT for patients with pancreatic
carcinoma and close or positive margins. Grade 3
toxicity occurred in 2 patients (4.1%), and local control
remained high at 77% at 2 years. This local control rate is
comparable with the rates reported in Radiation Therapy
Oncology Group (RTOG) study 9704 that assessed
adjuvant chemoradiation, including patients with both
positive and negative margins (72%-77%).23 Of note,
adjuvant chemoradiation is controversial, and randomized
controlled trials have demonstrated a range from no
benefit to a detriment on OS.16,24 These trials have since
been subjected to numerous criticisms, and the RTOG
0848 study is currently ongoing to clarify the role of
chemoradiation in patients with R0/R1 resection.
Our low toxicity profile is comparable with the profiles
of other prospective trials that utilized conventional
chemoradiation. RTOG 9704 was a randomized control
trial that evaluated the addition of gemcitabine to
fluorouracil chemotherapy for resected pancreatic
adenocarcinoma. Grade 2 toxicity ranged between 15%
and 21%.23 GITSG 9173 was another randomized control
trial that evaluated surgery with or without postoperative
chemoradiation for pancreatic adenocarcinoma. The
chemoradiation was administered in a split course
fashion, consisting of 2 courses of 20 Gy separated by
2 weeks. The results showed that 14% of patients had
hematologic toxicity, and 20% in the registered phase had
severe leukopenia. Our grade 3 was only 4.1%,
demonstrating that a high dose of radiation therapy can be
safely delivered without causing significant morbidity. Of
note, a large component of the toxicities reported in these
trials were secondary to chemotherapy, which was not
standard in the present report.
Conclusions
Adjuvant pancreatic SBRT is a safe and feasibility
option for patients with pancreatic carcinoma and close or
positive margins, because of its systemic dosing of
chemotherapy without interruption. The technique can
also be interdigitated safely between chemotherapy cycles
because adjuvant SBRT can be delivered in 1 week.
Although there is no apparent addition to any survival
benefit from chemotherapy alone, adjuvant SBRT appears
to improve local control without an adverse effect on
patient-reported quality of life. Further prospective trials,
including phase 3 trials, will needed to be performed to
allow for the implementation of this technique at other
institutions.
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